Abstract
DepoCyte is a slow-release formulation of cytarabine designed for intrathecal administration. The goal of this multi-centre cohort study was to determine the safety and efficacy of DepoCyte for the intrathecal treatment of neoplastic meningitis due to breast cancer. DepoCyte 50 mg was injected once every 2 weeks for one month of induction therapy; responding patients were treated with an additional 3 months of consolidation therapy. All patients had metastatic breast cancer and a positive CSF cytology or neurologic findings characteristic of neoplastic meningitis. The median number of DepoCyte doses was 3, and 85% of patients completed the planned 1 month induction. Median follow up is currently 19 months. The primary endpoint was response, defined as conversion of the CSF cytology from positive to negative at all sites known to be positive, and the absence of neurologic progression at the time the cytologic conversion was documented. The response rate among the 43 evaluable patients was 28% (CI 95%: 14–41%); the intent-to-treat response rate was 21% (CI 95%: 12–34%). Median time to neurologic progression was 49 days (range 1–515+); median survival was 88 days (range 1–515+), and 1 year survival is projected to be 19%. The major adverse events were headache and arachnoiditis. When drug-related, these were largely of low grade, transient and reversible. Headache occurred on 11% of cycles; 90% were grade 1 or 2. Arachnoiditis occurred on 19% of cycles; 88% were grade 1 or 2. DepoCyte demonstrated activity in neoplastic meningitis due to breast cancer that is comparable to results reported with conventional intrathecal agents. However, this activity was achieved with one fourth as many intrathecal injections as typically required in conventional therapy. The every 2 week dose schedule is a major advantage for both patients and physicians. © 2001 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Balm M and Hammack J (1996) Leptomeningeal carcinomatosis – presenting features and prognostic factors. Arch Neurol 53: 626–632
Bleyer WA and Dedrick RL (1977) Clinical pharmacology of intrathecal methotrexate. I. Pharmacokinetics in nontoxic patients after lumbar injection. Cancer Treat Rep 61: 703–708
Boogerd W, Hart AAM, Van der Sande JJ and Engelsman E (1991) Meningeal carcinomatosis in breast cancer. Cancer 67: 1685–1695
Chamberlain M and Kormanik P (1997) Prognostic significance of coexistent bulky metastatic central nerous system disease in patients with leptomeningeal metastases. Arch Neurol 54: 1364–1368
Chamberlain MC and Kormanik PRN (1997) Carcinomatous meningitis secondary to breast cancer: predictors of response to combined modality therapy. J Neurooncol 35: 55–64
Fizazi K, Asselain B, Vincent-Salomon A, Jouve M, Dieras V, Palangie T, Beuzeboc P, Dorval T and Pouillart P (1996) Meningeal carcinomatosis in patients with breast carcinoma. Cancer 77: 1315–1323
Giannone L, Greco FA and Hainsworth JD (1986) Combination intraventricular chemotherapy for meningeal neoplasia. J Clin Oncol 4: 68–73
Glantz MJ, Cole BF, Recht L, Akerley W, Mills P, Saris S, Hochberg F, Calabresi P and Egorin MJ (1998) High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: Is intrathecal chemotherapy necessary?. J Clin Oncol 16: 1561–1567
Glantz M, Jaeckle KA, Chamberlain MC, Phuphanich S, Recht L, Swinnen LJ, Maria B, LaFollette S, Schumann GB, Cole BF and Howell SB (1999) A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 5: 3394–3402
Graham FL and Whitmore GF (1970) The effect of 1-β-D-arabinofuranosyl-cytosine on growth, viability, and DNA synthesis of mouse L-cells. Cancer Res 30: 2627–2635
Grant R, Naylor B, Greenberg HS and Junck L (1994) Clinical outcome in aggresively treated meningeal carcinomatosis. Arch Neurol 51: 457–461
Grossman SA and Spence A (1999) NCCN clinical practice guidelines for carcinomatous/lymphomatous meningitis. Oncol 13: 144–152
Grossman SA, Finkelstein DM, Ruckdeschel JC, Trump DL, Moynihan T and Ettinger DS (1993) Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. J Clin Oncol 11: 561–569
Hitchins RN, Bell DR, Woods RL and Levi JA (1987) A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. J Clin Oncol 5: 1655–1662
Howell SB (1997) Regional chemotherapy. In: Holland J, Bast RC Jr., Morton DL, Frei E. III, Kufe DW and Weichselbau RR (eds.) Cancer Medicine, Fourth edition. Lea and Febiger: Philadelphia, pp 839–853
Jayson GC, Howell A, Harris M, Morgenstern G, Chang J and Ryder WD (1994) Carcinomatous meningitis in patients with breast cancer. An aggressive disease variant. Cancer 74: 3135–3141
Kim S, Chatelut E, Kim JC, Howell SB, Cates C, Kormanik PA and Chamberlain MC (1993) Extended CSF cytarabine exposure following intrathecal administration of DTC 101. J Clin Oncol 11: 2186–2193
Kohn FR, Malkmus SA, Brownson EA, Rossi SS and Yaksh TL (1998) Fate of the predominant phospholipid component of DepoFoam drug delivery matrix after intrathecal administration of sustained-release encapsulated cytarabine in rats. Drug Delivery 5: 143–151
Nakagawa H, Murasawa A, Kubo S, Nakajima S, Nakajima Y, Izumoto S and Hayakawa T (1992) Diagnosis and treatment of patients with meningeal carcinomatosis. J Neurooncol 13: 81–89
Ongerboer de Visser BW, Somers R, Nooyen WH, van Heerde P, Hart AAM and McVie JG (1983) Intraventricular methotrexate therapy of leptomeningeal metastasis from breast carcinoma. Neurol 33: 1565–1572
Shapiro WR, Young DF and Mehta BM (1975) Methotrexate distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. New Engl J Med 293: 161–166
Zimm S, Collins JM, Miser J, Chatterji D and Poplack DG (1984) Cytosine arabinoside cerebrospinal fluid kinetics. Clin Pharmacol Ther 35: 826–830
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Jaeckle, K., Phuphanich, S., Bent, M. et al. Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine. Br J Cancer 84, 157–163 (2001). https://doi.org/10.1054/bjoc.2000.1574
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1054/bjoc.2000.1574
Keywords
This article is cited by
-
Leptomeningeal Metastases
Current Treatment Options in Oncology (2018)
-
CSF CA 15-3 in breast cancer-related leptomeningeal metastases
Journal of Neuro-Oncology (2014)
-
Pharmacokinetics and efficacy of pemetrexed in patients with brain or leptomeningeal metastases
Journal of Neuro-Oncology (2013)
-
A retrospective case series of 103 consecutive patients with leptomeningeal metastasis and breast cancer
Journal of Neuro-Oncology (2013)
-
Optimal Management of Brain Metastases from Breast Cancer
CNS Drugs (2013)
